MedTrace Logo

Clinical Effectiveness of Tigecycline for Scrub Typhus.

NCT07513103 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-08-11

No results posted yet for this study

Summary

This multicenter, randomized, open-label clinical trial evaluated the efficacy and tolerability of intravenous tigecycline compared with oral doxycycline in adults hospitalized with scrub typhus. Participants were randomly assigned to receive either intravenous tigecycline or oral doxycycline. The primary efficacy outcome was time to defervescence, and tolerability was assessed based on reported adverse events.

Conditions

  • Scrub Typhus

Interventions

DRUG

doxycycline

Doxycycline 100 mg orally every 12 hours for 7 days.

DRUG

Tigecycline (Tygacil)

Tigecycline 100 mg intravenously as a loading dose, followed by 50 mg intravenously every 12 hours for 5 days.

Sponsors & Collaborators

  • Korean Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Jin Soo Lee

    lead OTHER

Principal Investigators

  • Jin-Soo Lee, MD., PhD. · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-19
Primary Completion
2024-12-10
Completion
2025-01-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07513103 on ClinicalTrials.gov